Is there reliable data on the post-rebate cost of the Humira vs biosimilar drugs in the US?
Humira biosimilars now controlling almost 40% of the market in the EU, according to Bernstein. The UK and Germany are outpacing the others... ...and the US looks on in shame, swallowing another 7.4% price increase from AbbVie for 2020pic.twitter.com/zUjbFNQhoa
-
-
-
this was Bernstein's slide on Humira prices in Europe...but no Humira biosimilars have launched in the USpic.twitter.com/cWN3G405pt
- Još 1 odgovor
Novi razgovor -
-
-
on the bright side, oncology biosimilars in the US are picking up speed and the 3 recent Pfizer launches should help https://www.bigmoleculewatch.com/2020/01/23/pfizer-announces-launches-and-pricing-information-for-three-u-s-biosimilars/ …pic.twitter.com/TkFJDZhMkk
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
Any thoughts on why infliximab biosimlars suffered a slower uptake than what we are seeing for oncology?
-
yes, as the Pfizer lawsuit from 2017 explained: J&J's exclusionary tactics are working, i.e. Pfizer claims that J&J tells insurers, "If you want to receive attractive rebates on Remicade for all your existing Remicade patients, you must agree to not reimburse for Inflectra"
- Još 1 odgovor
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.